[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Choi IK, Kim BS, Lee KA, Ryu S, Seo HY, Sul H, Choi JG, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Shin SW, Yoon SY, Cho Y, Kim YK, Kim YH, Kim JS: Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. Am J Hematol; 2004 Dec;77(4):366-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
  • Chronic neutrophilic leukemia (CNL) is a rare hematologic disorder, for which there is no standard therapy.
  • Recently, STI (imatinib mesylate) has been shown to be effective in treating patients with chronic myeloproliferative disorder (CMPD) displaying the translocation of the PDGFbetaR gene.
  • Here, we present a case of a patient with CNL carrying t(15;19)(q13;p13.3) who achieved a cytogenetic remission following treatment with imatinib, 400 mg daily.
  • After failure of alpha interferon and hydroxyurea therapy, a durable and complete clinical and cytogenic remission was induced by imatinib.
  • To our knowledge, this is the first case with CNL who showed complete response with cytogenic remission after treatment of imatinib.
  • The patient remains in complete remission with an excellent performance status after 7 months of therapy.
  • We demonstrate here that imatinib can induce a clinical and cytogenetic response in a case of CNL associated with a novel translocation other than a 5q33 rearrangement.
  • Further studies including the molecular cloning of the t(15;19)(q13;p13.3) will be important in understanding the pathophysiology of CNL with a heterogeneous clinical course and the exploitation of the basic mechanisms of imatinib treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Neutrophilic, Chronic / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor beta / genetics
  • [MeSH-minor] Benzamides. Biopsy, Needle. Bone Marrow / pathology. Humans. Imatinib Mesylate. Leukocyte Count. Male. Middle Aged. Neutrophils / pathology. Remission Induction. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15551277.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


2. Mithraprabhu S, Grigoriadis G, Khong T, Spencer A: Deactylase inhibition in myeloproliferative neoplasms. Invest New Drugs; 2010 Dec;28 Suppl 1:S50-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MPNs include eight haematological disorders: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), systemic mastocytosis (SM), chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), chronic neutrophilic leukemia (CNL), and unclassifiable MPN (MPN, U).
  • Therapeutic interventions for MPNs include the use of tyrosine kinase inhibitors (TKIs) for BCR-ABL1(+) CML and JAK2 inhibitors for PV, ET and PMF.
  • Histone deacetylase inhibitors (HDACi) are a novel class of drugs capable of altering the acetylation status of both histone and non-histone proteins, thereby affecting a repertoire of cellular functions in neoplastic cells including proliferation, differentiation, immune responses, angiogenesis and survival.
  • This review provides a review of pre-clinical and clinical studies that have explored the use of HDACi as potential therapeutics for MPNs.
  • [MeSH-major] Histone Deacetylase Inhibitors / therapeutic use. Histone Deacetylases / metabolism. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / enzymology
  • [MeSH-minor] Animals. Epigenesis, Genetic / drug effects. Humans. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2003 Nov 20;46(24):5097-116 [14613312.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):672-7 [14744784.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):627-38 [15023334.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] Expert Opin Investig Drugs. 2007 May;16(5):659-78 [17461739.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1115-23 [17267032.001]
  • [Cites] Blood. 2007 Jul 1;110(1):313-22 [17363733.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):503-14 [17610380.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9 [17613547.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6417-24 [17616702.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4280-90 [17634558.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1827-8 [17460705.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5420-32 [17694083.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Sep;322(3):1084-92 [17569822.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Cancer J. 2007 Nov-Dec;13(6):377-83 [18032975.001]
  • [Cites] Leukemia. 2008 Apr;22(4):740-7 [18079739.001]
  • [Cites] Br J Haematol. 2008 May;141(4):504-11 [18318760.001]
  • [Cites] Leukemia. 2008 May;22(5):965-70 [18385750.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1638-40 [18440067.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):375-80 [18636159.001]
  • [Cites] Blood. 2008 Aug 1;112(3):793-804 [18505786.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1636-8 [18305559.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):1920-30 [18511598.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1886-93 [18591380.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6106-15 [18829489.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3065-72 [18650451.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1635-44 [18815196.001]
  • [Cites] Leukemia. 2008 Nov;22(11):1990-8 [18843285.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):185-98 [18804549.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2231-2 [19052966.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2321-7 [19052980.001]
  • [Cites] Nat Rev Genet. 2009 Jan;10(1):32-42 [19065135.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6693-701 [15235588.001]
  • [Cites] Oncogene. 1998 Jul 2;16(26):3461-9 [9692554.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1239-44 [10022130.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2705-12 [15517875.001]
  • [Cites] Int J Mol Med. 2005 Jan;15(1):169-72 [15583844.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1768-76 [15514006.001]
  • [Cites] Med Res Rev. 2005 May;25(3):261-309 [15717297.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):741-3 [15908787.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1579-89 [16015388.001]
  • [Cites] Gene. 2005 Dec 19;363:15-23 [16289629.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1188-96 [16444746.001]
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3339-41 [16352805.001]
  • [Cites] Free Radic Biol Med. 2006 Jun 15;40(12):2175-82 [16785031.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):345-56 [17457302.001]
  • [Cites] Leukemia. 2009 Jan;23(1):180-2 [18509350.001]
  • [Cites] Cancer Lett. 2009 May 8;277(1):8-21 [18824292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 12;106(19):7751-5 [19416910.001]
  • [Cites] Ann Hematol. 2009 Jul;88(7):699-700 [19030859.001]
  • [Cites] Exp Cell Res. 2009 Jul 1;315(11):1809-18 [19268463.001]
  • [Cites] Eur J Haematol. 2009 Jul;83(1):48-56 [19226363.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8A):1437-50 [19522842.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7612-8 [19752087.001]
  • [Cites] Blood. 2009 Dec 3;114(24):5024-33 [19828702.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3109-17 [20130243.001]
  • [Cites] Leuk Res. 2010 Sep;34(9):1132-8 [20206383.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):427-42 [20478526.001]
  • [Cites] Blood. 2006 Jul 15;108(2):645-52 [16537804.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1058-64 [16861352.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1071-6 [16892059.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5869-78 [17020995.001]
  • [Cites] Blood Cells Mol Dis. 2006 Nov-Dec;37(3):210-7 [16978890.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Ann Intern Med. 2006 Dec 19;145(12):913-23 [17179059.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):165-73 [16990584.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Leukemia. 2007 Mar;21(3):505-10 [17230231.001]
  • [Cites] Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6 [17350297.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2049-55 [10766197.001]
  • [Cites] Mol Biol Cell. 2000 Jun;11(6):2069-83 [10848630.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20436-43 [10777477.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):2-11 [10930974.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39223-30 [11010972.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22491-9 [11304533.001]
  • [Cites] Cell Mol Life Sci. 2001 May;58(5-6):728-36 [11437234.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Mol Pharmacol. 2001 Oct;60(4):828-37 [11562446.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Adv Cancer Res. 2002;86:41-65 [12374280.001]
  • [Cites] Semin Hematol. 2003 Jan;40(1):22-33 [12563609.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3236-9 [12446442.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5126-35 [12941844.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3765-74 [12893773.001]
  • (PMID = 21127942.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC3003795
  •  go-up   go-down


3. Moles MP, Landry J, Roche-Lestienne C, Godon A, Schmidt-Tanguy A, Gardembas M, Le Clech C, Verret JL, Zandecki M, Blanchet O: [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]. Ann Biol Clin (Paris); 2005 May-Jun;63(3):317-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
  • Idiopathic hypereosinophilic syndrome is characterised by chronic hypereosinophilia leading to tissue damage, and after exclusion of reactive eosinophilia.
  • Until recently no specific or efficient therapeutic was available.
  • The resulting protein has constitutive tyrosine kinase activity which explains clinical and cytological remission of hypereosinophilic syndrome after treatment by a specific tyrosine kinase inhibitor, imatinib mesylate or Glivec, usually used in chronic myeloid leukaemia.
  • Here we report a patient with hypereosinophilic syndrome associated to peculiar morphology of neutrophilic series and the 4q12 deletion.
  • He presented clinical and haematological remission since the introduction of imatinib mesylate therapy.
  • [MeSH-major] Hypereosinophilic Syndrome / drug therapy. Hypereosinophilic Syndrome / pathology. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • Genetic Alliance. consumer health - Idiopathic hypereosinophilic syndrome.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951264.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


Advertisement
4. Bhave AA, Rao RG, Patil GT: Rare presentation of leucocytosis. J Assoc Physicians India; 2006 Nov;54:881-2
Hazardous Substances Data Bank. Allopurinol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following relevant investigations, we diagnosed him to have Chronic Neutrophilic Leukaemia (CNL); a rare haematological disorder.
  • Ten months later, he remains non-responsive to standard line of treatment.
  • [MeSH-major] Leukemia, Neutrophilic, Chronic / diagnosis. Leukemia, Neutrophilic, Chronic / drug therapy
  • [MeSH-minor] Adult. Allopurinol / therapeutic use. Humans. Hydroxyurea / therapeutic use. Leukocytosis / diagnosis. Male. Prognosis. Vitamins / therapeutic use

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249258.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Vitamins; 63CZ7GJN5I / Allopurinol; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


5. Telek B, Batár P, Udvardy M, László R: [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature]. Orv Hetil; 2006 May 7;147(18):827-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].
  • Chronic neutrophilic leukemia is an uncommon hematological entity.
  • In the last 20 years seven patients have been diagnosed with chronic neutrophilic leukemia at our department.
  • All but one had splenomegaly, two patients developed severe anaemia and in one case thrombocytosis was present at the time of diagnosis.
  • White blood cell count ranged between 39 x 10(9)/1-71 x 10(9)/l with 80% of neutrophils and striking myeloid hyperplasia were present in the bone marrow without evidence of any dysplasia resembling chronic myelocytic leukemia.
  • Three of them died due to progression of chronic neutrophilic leukemia.
  • One patient, initially receiving hydroxyurea + interferon therapy and showing progression, developed complete hematological remission with an eight week imatinib mesylate (Glivec) treatment.
  • Beside of their own experiences the authors review the current literature and discuss differential diagnostic and therapeutic challenges, as well.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Neutrophilic, Chronic / diagnosis. Leukemia, Neutrophilic, Chronic / drug therapy
  • [MeSH-minor] Aged. Benzamides. Diagnosis, Differential. Humans. Hungary. Hydroxyurea / administration & dosage. Imatinib Mesylate. Interferons / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Male. Middle Aged. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Retrospective Studies. Splenomegaly / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784137.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9008-11-1 / Interferons; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


6. Elliott MA, Dewald GW, Tefferi A, Hanson CA: Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia; 2001 Jan;15(1):35-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study.
  • This report describes a single institution's recent experience with six patients fulfilling the diagnostic criteria of chronic neutrophilic leukemia.
  • Two patients demonstrated clonal evolution during the course of the disease.
  • All responded initially to therapy with hydroxyurea with control of leukocytosis and reduction in splenomegaly.
  • Aggressive chemotherapy to control progressive leukocytosis resulted in death due to cytopenias in two of these patients.
  • The third patient received less intensive chemotherapy and died of progressive disease.
  • One patient died after transformation of the disease into undifferentiated acute myeloid leukemia.
  • Two patients remain alive with stable disease on hydroxyurea therapy, 12 and 54 months after initial diagnosis.
  • Chronic neutrophilic leukemia is a rare clinicopathologic entity that can be distinguished from chronic myelogenous leukemia, the recently described neutrophilic-chronic myelogenous leukemia, and myelodysplastic syndrome.
  • The clinical course is heterogeneous, with a definite risk of death from either blastic transformation or progressive neutrophilic leukocytosis.
  • [MeSH-major] Leukemia, Neutrophilic, Chronic

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11243396.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


7. Yoshida C, Kojima H, Iijima T, Katsura Y, Shimizu S, Suzukawa K, Mukai HY, Hasegawa Y, Abei M, Nagasawa T: Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia. Eur J Haematol; 2004 Mar;72(3):225-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia.
  • A 54-yr-old female having chronic neutrophilic leukemia (CNL) associated with severe liver injury is presented.
  • There was no abnormality in serum cholesterol, triglyceride, or glucose levels.
  • As the patient had no history of alcohol abuse, a diagnosis of non-alcoholic steatohepatitis (NASH) was made.
  • Assuming that the infiltration of abnormal neutrophils into the liver contributed to the development of NASH, she was treated with cytoreductive chemotherapy (cytosine arabinoside: 100 mg/d, 1-3 doses/wk).
  • To our knowledge, this is the first report describing the development of NASH in a myeloproliferative disorder.
  • [MeSH-major] Fatty Liver / etiology. Leukemia, Neutrophilic, Chronic / complications
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Cytarabine / therapeutic use. Female. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Genetic Alliance. consumer health - Non-alcoholic steatohepatitis (NASH).
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14962243.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


8. Piliotis E, Kutas G, Lipton JH: Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia. Leuk Lymphoma; 2002 Oct;43(10):2051-4
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia.
  • Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder characterized by a clonal proliferation of mainly mature neutrophils, which is often difficult to differentiate from reactive leukocytosis or other myeloproliferative disorders.
  • Treatment to date has focused on disease control rather than cure.
  • Once the disease has progressed to a more aggressive leukemia there is typically little chance of obtaining a long lasting remission due to the older age of most patients as well as the acquisition of multiple poor prognostic cytogenetic abnormalities.
  • In this case report we describe a successful sibling allogeneic bone marrow transplant in a 60-year-old man with CNL performed while he was still in the stable phase of his disease.
  • We propose that even in older patients this curative approach may be considered in selected patients at an early stage of their disease, similar to the approach taken with chronic myelogenous leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Neutrophilic, Chronic / therapy
  • [MeSH-minor] Disease Management. Disease-Free Survival. Graft Survival. Graft vs Host Disease / drug therapy. Humans. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12481908.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Willard RJ, Turiansky GW, Genest GP, Davis BJ, Diehl LF: Leukemia cutis in a patient with chronic neutrophilic leukemia. J Am Acad Dermatol; 2001 Feb;44(2 Suppl):365-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis in a patient with chronic neutrophilic leukemia.
  • Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder.
  • We report the first case of CNL with an associated leukemia cutis.
  • CNL was diagnosed in a 74-year-old white woman in 1998, based on neutrophilic infiltration of the bone marrow and absence of the Philadelphia chromosome.
  • The patient presented to the dermatology service in August 1998 with a 2-week history of a pruritic eruption on the arms, hands, and legs.
  • Leukemia cutis was demonstrated on biopsy specimens of several lesional sites.
  • The eruption progressed, despite treatment with topical and systemic corticosteroids.
  • Treatment with systemic chemotherapy did affect partial resolution of the eruption, with parallel decreases in bone pain and white blood cell count, but the disease progressed and the patient ultimately died 5 months after her initial skin findings.
  • Only one other case of CNL with dermatologic manifestations has been reported, CNL associated with a reactional neutrophilic dermatosis.
  • The importance of distinguishing the specific infiltrates of leukemia from the nonspecific infiltrates of reactional dermatoses, such as Sweet's syndrome, is illustrated.
  • [MeSH-major] Leukemia / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Skin / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Bone Marrow Cells / pathology. Disease Progression. Fatal Outcome. Female. Hand Dermatoses / diagnosis. Humans. Leg Dermatoses / diagnosis

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11174417.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P: Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation. Chin Med J (Engl); 2008 Sep 20;121(18):1770-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
  • BACKGROUND: Relapse remains an obstacle to successful allogeneic haematopoietic stem cell transplantation (allo-HSCT) for patients with acute leukaemia and no standard treatment is available.
  • We assessed fludarabine and cytarabine with transfusion of donor haematopoietic stem cell in treating the relapse of acute leukaemia after allo-HSCT.
  • METHODS: Seven patients, median age 34 years, with relapse of acute leukaemia after allo-HSCT received combination chemotherapy of fludarabine with cytarabine for 5 days.
  • Five patients suffered from acute myeloid leukaemia (2 refractory) and 2 refractory acute lymphoblastic leukaemia.
  • After the transplantation, the median relapse time was 110 days (range, 38 - 185 days).
  • Two days after chemotherapy, 5 patients received infusion of donor's peripheral blood stem cells, mobilized by granulocyte colony stimulating factor.
  • DNA sequence analysis at day 30 after treatment identified all as full donor chimera type.
  • The median observation time was 189 days.
  • After the treatment, the median time for neutrophilic granulocyte value = 0.5 x 10(9)/L and for platelet value = 20 x 10(9)/L were 13 days (range, 10 - 18 days) and 15 days (range, 11 - 24 days), respectively.
  • Graft versus host disease occurred in 2 patients (acute) and 3 (chronic).
  • The other patients died of leukaemia related deaths.
  • Three patients with chronic graft versus host disease who had received donor peripheral blood stem cells reinfusion have survived for 375 days, 232 days and 195 days, respectively.
  • CONCLUSIONS: Fludarabine with cytarabine plus the donor haematopoietic stem cell should be considered as an effective therapeutic regimen for relapse of acute leukaemia after allo-HSCT.
  • The disease free state of patients may increase, though with high risk of secondary fungal infection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080355.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


11. Gómez Vázquez M, Peteiro C, Toribio J: Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia. J Eur Acad Dermatol Venereol; 2003 May;17(3):328-30
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia.
  • Neutrophilic eccrine hidradenitis was initially described in acute myelogenous leukaemic patients undergoing chemotherapy, suggesting a drug-induced mechanism.
  • However, most the reported cases have been described in acute myelogenous leukaemic cases receiving chemotherapy.
  • We describe a neutrophilic eccrine hidradenitis case unassociated with chemotherapy in a woman with chronic myelogenous leukaemia.
  • [MeSH-major] Hidradenitis / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Axilla. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12702078.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. van Hirtum PV, Prins M, ten Oever J, Nijziel MR, Vreugdenhil G, Dercksen MW: [Sweet syndrome in underlying malignancy]. Ned Tijdschr Geneeskd; 2010;154:A2112
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sweet syndrome, also known as acute febrile neutrophilic dermatosis, was diagnosed in two patients.
  • Patient A, a 68-year-old man, had had chronic lymphatic leukaemia for four years, with a recent relapse.
  • Both patients presented with general discomfort, high fever, neutrophilic leukocytosis and diffuse, non-tender maculopapular exanthema, partly blanching on applied pressure, and vesicles spread over the body.
  • It is important to recognise the varied clinical picture of the rare disorder that is Sweet syndrome because it can lead to severe clinical illness, especially in patients with an underlying malignancy.
  • [MeSH-major] Neoplasms / complications. Prednisone / therapeutic use. Sweet Syndrome / diagnosis. Sweet Syndrome / drug therapy. Sweet Syndrome / etiology
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / diagnosis. Disease Progression. Follow-Up Studies. Humans. Kidney Neoplasms / diagnosis. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21040604.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


13. Gning SB, Debonne JM, Diagne-Guèye NM, Ndiaye B, Fall F, Mbaye PS: [Leg ulcer due to hydroxyurea. A case report]. Dakar Med; 2006;51(2):89-91
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ulcère de jambe lié a l'hydroxyurée. A propos d'une observation.
  • She was followed since 2001 for a chronic myelogenous leukaemia, and took hydroxyurea at a rate of 1500 mg per day, with a good clinical and hematologic answer.
  • The hemogram showed a hyperleucocytosis with 24.000 white elements/mm3 with neutrophilic polynucleosis.
  • Its occurrence imposes the final stop of the treatment.
  • [MeSH-minor] Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Middle Aged

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632983.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Senegal
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down






Advertisement